Rabies vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ImmunogenicityMalariaImmune ResponseMonoclonalRift Valley Fever

98 competitors in Immunogenicity

#DrugCompanyPhaseTrials

1

Perjeta

Roche

Phase 3

22

Prolia

OOrganon and Co

Phase 3

23

Rabies vaccine

Novartis

Phase 3

124

Rsvpref

Pfizer

Phase 3

55

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

36

PCV21

Sanofi

Phase 3

27

Bexsero

GSK

Phase 3

88

Gardasil-9

BBeijing Health Guard Biotechnology, Inc

Phase 3

29

Opfolda

Johnson & Johnson

Phase 3

110

Menacyw Conjugate Vaccine

Sanofi

Phase 3

7Show 31 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity12 trials

Safety and Immunogenicity of ID vs IM Rabies Vaccine

Not yet recruiting·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 2/3·NCT07345208·90 enrolled

Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso

Completed·UUniversity of Oxford·Phase 1/2·NCT03896724·450 enrolled

Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania

Completed·UUniversity of Oxford·Phase 1·NCT03435874·63 enrolled

Show 9 more trials

Immunogenicity of Rabies Vaccine for Pre Exposure Prophylaxis

Completed·SState University of New York - Upstate Medical University·Phase 4·NCT02374814·60 enrolled

Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children

Unknown status·QQueen Saovabha Memorial Institute··NCT02339896·45 enrolled

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age

Completed·Novartis·Phase 3·NCT02177032·885 enrolled

A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults

Completed·Novartis·Phase 3·NCT01466387·552 enrolled

Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen

Not yet recruiting·Sinovac Biotech Co., Ltd·Phase 3·NCT07055893·390 enrolled

Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins

Completed·QQueen Saovabha Memorial Institute·N/A·NCT01641315·75 enrolled

Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years

Unknown status·AAfrican Malaria Network Trust·Phase 1·NCT00703066·30 enrolled

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Unknown status·CChina National Biotec Group Company Limited·Phase 4·NCT05453487·360 enrolled

Dosage-Escalation Study of the Safety and Immunogenicity of a Novel Rabies Vaccine ChAd155-RG vs. the Comparator RABAVERT Vaccine in Healthy Adult Subjects

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04019444·50 enrolled

Malaria9 trials

Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali

Completed·UU.S. Army Medical Research and Development Command·Phase 2·NCT00460525·400 enrolled

FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali

Completed·UU.S. Army Medical Research and Development Command·Phase 1·NCT00349713·60 enrolled

A Study to Test Experimental Blood Stage Malaria Vaccine in Burkina Faso.

Recruiting·UUniversity of Oxford·Phase 1/2·NCT05790889·480 enrolled

Show 6 more trials

A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso

Completed·UUniversity of Oxford·Phase 1/2·NCT01635647·730 enrolled

Efficacy of Malaria Vaccines in Kenyan Adults

Completed·UUniversity of Oxford·Phase 2·NCT01666925·120 enrolled

Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.

Completed·SState University of New York - Upstate Medical University·Phase 4·NCT02564471·103 enrolled

R21/Matrix-M in African Children Against Clinical Malaria

Active, not recruiting·UUniversity of Oxford·Phase 3·NCT04704830·4,800 enrolled

Efficacy of Candidate Malaria Vaccines in Senegalese Adults

Completed·UUniversity of Oxford·Phase 2·NCT01658696·120 enrolled

Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age

Completed·GSK·Phase 2·NCT03276962·1,500 enrolled

Immunization3 trials

Rabies Immunization Concomitant With JEV in Children

Completed·MMahidol University·Phase 2·NCT00703521·200 enrolled

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Completed·CChangchun Zhuoyi Biological Co., Ltd·Phase 3·NCT05549908·1,800 enrolled

Early Rabies Vaccine Immunization in Primary School Children

Completed·PProvincial Public Health Office, Phetchabun·Phase 3·NCT01107275·703 enrolled

Vaccine2 trials

Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

Completed·Novartis·Phase 3·NCT00345319·630 enrolled

The Protection Effect of Speeda® Rabies Vaccine for Human Use

Completed·BBeijing Center for Disease Control and Prevention·Phase 4·NCT01827917·37 enrolled

Immune2 trials

Rabies Immune Plasma Booster Study

Completed·CSL Behring··NCT01063140·491 enrolled

Increasing HAART-Induced Immune Restoration With Cyclosporine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00031070·40 enrolled

Details

Drug Info

Related News